On July 17, Gelunhui reported that Mr. Dai Lizhong, the actual controller and chairman of Sansure Biotech Inc.(688289.SH), proposed to formulate and implement the mid-term dividend plan for 2024, based on the total share capital of the company less the shares in the repurchase special securities account, and to pay a cash dividend of RMB 2.50 (tax included) per 10 shares to all shareholders, subject to the profit distribution principles stipulated in the Company's Articles of Association to ensure the normal operation and long-term development of the company. The specific profit distribution plan shall be determined by the company based on its own business conditions and submitted to the board of directors and shareholders' meeting for approval.
To enhance the long-term investment value of the company, further strengthen investor confidence, and reduce the registered capital by canceling 1 million shares originally used for employee shareholding plans or stock-based incentives in the repurchase special securities account, thus effectively increasing the investment return to shareholders by raising the EPS level, and further delivering the company's firm confidence and high recognition of its own long-term intrinsic value to investors.